LinAge2 Comprehensive Health Age Screen

LinAge2 Comprehensive Health Age Screen: Domain Panel Specifications

Clinical Q&A: LinAge2 Comprehensive Health Age Screen

What neurological biomarkers does LinAge2 measure and why do they matter for early detection?

The neurological domain of LinAge2 is distinguished from other longevity assessments by the inclusion of plasma biomarkers now validated as pre-symptomatic indicators of neurodegeneration. Neurofilament light chain (NfL) is a structural protein released into the bloodstream when axons are damaged or degenerate — plasma NfL begins rising measurably 10–20 years before clinical symptoms of Alzheimer's disease, Parkinson's disease, and multiple sclerosis emerge. A longitudinal study in the New England Journal of Medicine (Preische et al., 2019) demonstrated plasma NfL elevation 16 years before estimated symptom onset in genetic Alzheimer's cases. Glial fibrillary acidic protein (GFAP) is released by reactive astrocytes during neuroinflammation and amyloid pathology — plasma GFAP elevation predicts amyloid positivity on PET scanning with approximately 80% sensitivity. BDNF (brain-derived neurotrophic factor) reflects neuroplasticity capacity; below 20 ng/mL is associated with accelerated hippocampal volume loss, treatment-resistant depression, and cognitive decline rate. These biomarkers transform neurological health age from a subjective cognitive impression into an objective, trackable biomarker trajectory — enabling pre-symptomatic intervention through aerobic exercise (the most potent BDNF elevator), sleep optimisation (critical for amyloid clearance via the glymphatic system), and metabolic control (chronic hyperinsulinaemia is the strongest modifiable driver of Alzheimer's risk in Singapore's population).

How is immunological age measured and what does an elevated immune age indicate?

Immunological ageing (immunosenescence) is characterised by progressive accumulation of exhausted, senescent T-cells — specifically CD28-negative, CD57-positive effector memory T-cells that have lost co-stimulatory capacity and upregulate inhibitory receptors. The ratio of CD28-/CD57+ T-cells to naive T-cells rises with age and with chronic viral infection burden (particularly CMV, which colonises 70–80% of Singapore adults over 40). An elevated CD28-/CD57+ ratio indicates depleted immune repertoire diversity and reduced capacity for de novo immune responses — manifesting as greater susceptibility to novel infections, impaired vaccine response, and reduced cancer immune surveillance. The SASP cytokine panel (IL-6, TNF-alpha, GDF-15, IL-8, MMP-3) quantifies the chronic sterile inflammatory state driven by senescent cells — elevated SASP is independently associated with all-cause mortality, cardiovascular events, and cognitive decline in longitudinal data. NAD+ insufficiency impairs both the SIRT1-mediated deacetylation pathways governing inflammatory gene expression and the PARP1-dependent DNA repair capacity in lymphocytes. The immune age domain of LinAge2 thus integrates cellular immunosenescence, inflammageing burden, and metabolic immune capacity into a single actionable immune health age metric.

What distinguishes LinAge2 from the Advanced Cellular Blueprint and when is each preferred?

The Advanced Cellular Blueprint focuses on six domains with maximum depth per domain — particularly excelling in its cellular senescence panel (p16INK4a + full SASP), mitochondrial function assessment (8-OHdG, MDA, CoQ10, citrate synthase), and telomere length measurement. LinAge2's differentiation is its neurological health age domain — plasma NfL, GFAP, BDNF, and cognitive function battery — which the Blueprint does not include. This makes LinAge2 the preferred choice for individuals with a family history of neurodegeneration, those noticing subjective cognitive changes, or longevity optimisers who prioritise brain health alongside metabolic and cardiovascular ageing. For individuals primarily concerned with cellular-level ageing mechanics (senescence, mitochondria, telomeres), the Blueprint provides deeper domain specificity. For those wanting maximum neurological coverage alongside comprehensive multi-system biological age, LinAge2 is the appropriate choice. Both tests are positioned at the same tier of longevity assessment and can be compared longitudinally at 12-month intervals.

How is the Integrated Health Age Score calculated and weighted?

The Integrated Health Age Score is a composite metric calculated from the six domain-specific Z-scores — each domain's result expressed as standard deviations above or below the age-sex-matched Singapore population mean. Domain weighting in the composite reflects both mortality prediction strength and modifiability: cardiovascular and metabolic domains carry higher composite weighting because they are (a) the strongest mortality predictors in the Singapore epidemiological context and (b) the most responsive to lifestyle intervention within a 90-day timeframe. Epigenetic age carries significant weighting as the only domain that directly measures accumulated biological ageing rather than disease risk. Neurological and immune domains receive lower composite weighting due to their longer intervention timescales, but are prioritised in the protocol if their Z-scores are highly elevated. The final Health Age Score is expressed as a biological age in years, enabling direct comparison to chronological age — a 45-year-old with a Health Age Score of 52 has an overall biological age 7 years ahead of their chronological age, with the system-by-system report identifying which of the six domains drives this acceleration and to what degree.

What metabolic biomarkers detect insulin resistance before HbA1c elevation?

HbA1c reflects average blood glucose over 90 days and only rises above the pre-diabetic threshold (39 mmol/mol) after substantial beta-cell compensation failure has already occurred. Insulin resistance — the upstream driver of type 2 diabetes — is detectable years earlier through fasting insulin and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance: fasting glucose mmol/L × fasting insulin mIU/L ÷ 22.5). HOMA-IR above 2.5 indicates clinically significant insulin resistance in Asian populations (lower threshold than 3.0 used in European populations, reflecting the differential metabolic susceptibility of Singapore's multi-ethnic population). The Triglyceride-to-HDL ratio (TG/HDL-C) above 1.3 mmol/L in Asian populations is a validated surrogate for LDL particle density and insulin resistance burden. GGT elevation (above 25 U/L in women, 40 U/L in men) reflects hepatic lipid accumulation and oxidative stress preceding NAFLD diagnosis. LinAge2's metabolic health age integrates these pre-HbA1c insulin resistance markers to identify metabolic ageing at the stage when intervention is most effective — before the pancreatic beta-cell exhaustion that makes HbA1c-detected pre-diabetes substantially harder to reverse.

Regulatory & Standards Framework: All laboratory analyses under ISO 15189:2022 (Medical laboratories — Requirements for quality and competence). Hormonal assays per CDC Hormone Standardisation (HoSt) Program. Cardiovascular biomarkers (ApoB, Lp(a)) per WHO/IFCC International Reference Preparations. Cognitive function battery per validated neuropsychological assessment frameworks (RBANS, MoCA). Plasma NfL and GFAP assays (Quanterix Simoa HD-X platform or equivalent ultra-sensitive immunoassay). GrimAge/PhenoAge: Lu AT et al., Nature Aging 2019; Levine ME et al., Aging 2018. Plasma NfL and neurodegeneration: Preische O et al., New England Journal of Medicine 2019. GFAP and amyloid prediction: Benedet AL et al., JAMA Neurology 2021. Singapore MOH regulated clinical laboratory and nursing services environment; EMIS+ nurses registered under Singapore Nursing Board (SNB).